155 related articles for article (PubMed ID: 28435463)
41. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
42. Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.
Zeiderman MR; Egger ME; Kimbrough CW; England CG; Dupre TV; McMasters KM; McNally LR
J Surg Res; 2014 Jul; 190(1):111-8. PubMed ID: 24655664
[TBL] [Abstract][Full Text] [Related]
43. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
Nagasawa I; Kunimasa K; Tsukahara S; Tomida A
Biochem Biophys Res Commun; 2017 Jan; 482(4):1491-1497. PubMed ID: 27965097
[TBL] [Abstract][Full Text] [Related]
44. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J
Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401
[TBL] [Abstract][Full Text] [Related]
45. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
46. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
[TBL] [Abstract][Full Text] [Related]
47. When are signal transduction targeted therapies acting as immunotherapy?
Flaherty KT
Cancer Biol Ther; 2015; 16(5):645-7. PubMed ID: 25807058
[TBL] [Abstract][Full Text] [Related]
48. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
49. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
[TBL] [Abstract][Full Text] [Related]
50. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
51. Painful nipple hyperkeratosis secondary to vemurafenib.
Carr ES; Brown SC; Fiala KH
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
[TBL] [Abstract][Full Text] [Related]
52. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
[TBL] [Abstract][Full Text] [Related]
54. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
55. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
56. Combined inhibition of BRAF and MEK in melanoma patients.
Infante JR; Swanton C
Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140
[No Abstract] [Full Text] [Related]
57. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
[TBL] [Abstract][Full Text] [Related]
58. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
59. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA
Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
